Molar mass 755.9 g/mol | ChemSpider ID 24651717 | |
 | ||
Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing.
In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep.
References
Vaniprevir Wikipedia(Text) CC BY-SA